Detalles de la búsqueda
1.
Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?
Br J Cancer
; 118(2): 248-257, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29123264
2.
Phase I study of PM00104 (Zalypsis®) administered as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors.
Invest New Drugs
; 31(3): 623-30, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22688291
3.
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma.
EClinicalMedicine
; 60: 102015, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37287870
4.
COVID-19 and liver cancer: lost patients and larger tumours.
BMJ Open Gastroenterol
; 9(1)2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35450934
5.
NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
Clin Cancer Res
; 13(5): 1584-90, 2007 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-17332305
6.
The use of circulating biomarkers in early clinical trials in patients with cancer.
Biomark Med
; 9(10): 1011-23, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26441037
7.
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker.
Clin Lung Cancer
; 16(5): 348-57, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25700774
Resultados
1 -
7
de 7
1
Próxima >
>>